Cost-effectiveness of different human papillomavirus vaccines in Singapore

Lee, Vernon J.; Tay, Sun Kuie; Teoh, Yee Leong; Tok, Mei Yin
January 2011
BMC Public Health;2011, Vol. 11 Issue 1, p203
Academic Journal
Background: Human papillomavirus (HPV) vaccines are widely available and there have been studies exploring their potential clinical impact and cost-effectiveness. However, few studies have compared the cost-effectiveness among the 2 main vaccines available - a bivalent vaccine against HPV 16/18, and a quadrivalent vaccine against 6/ 11/16/18. We explore the cost-effectiveness of these two HPV vaccines in tropical Singapore. Methods: We developed a Markov state-transition model to represent the natural history of cervical cancer to predict HPV infection, cancer incidence, mortality, and costs. Cytologic screening and treatment of different outcomes of HPV infection were incorporated. Vaccination was provided to a cohort of 12-year old females in Singapore, followed up until death. Based on available vaccines on the market, the bivalent vaccine had increased effectiveness against a wider range of HPV types, while the quadrivalent vaccine had effectiveness against genital warts. Incremental cost-effectiveness ratios (ICER) compared vaccination to no-vaccination, and between the two vaccines. Sensitivity analyses explored differences in vaccine effectiveness and uptake, and other key input parameters. Results: For the no vaccination scenario, 229 cervical cancer cases occurred over the cohort's lifetime. The total discounted cost per individual due to HPV infection was SGD$275 with 28.54 discounted life-years. With 100% vaccine coverage, the quadrivalent vaccine reduced cancers by 176, and had an ICER of SGD$12,866 per life-year saved. For the bivalent vaccine, 197 cancers were prevented with an ICER of $12,827 per life-year saved. Comparing the bivalent to the quadrivalent vaccine, the ICER was $12,488 per life-year saved. However, the cost per QALY saved for the quadrivalent vaccine compared to no vaccine was $9,071, while it was $10,392 for the bivalent vaccine, with the quadrivalent vaccine dominating the bivalent vaccine due to the additional QALY effect from reduction in genital warts. The overall outcomes were most sensitive to vaccine cost and coverage. Conclusion: HPV vaccination is a cost-effective strategy, and should be considered a possible strategy to reduce the impact of HPV infection.


Related Articles

  • Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. Jit, Mark; Chapman, Ruth; Hughes, Owain; Choi, Yoon Hong // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;10/1/2011, Vol. 343 Issue 7825, p677 

    The article reports on the study related to the effect and cost effectiveness of the bivalent and quadrivalent human papillomavirus (HPV) vaccination. It states that bivalent vaccines have advantage in preventing death due to its cost effectiveness. It also informs that quadrivalent vaccines...

  • Human papillomavirus genotypes in women with invasive cervical cancer with and without human immunodeficiency virus infection in Botswana. Tawe, Leabaneng; MacDuffie, Emily; Narasimhamurthy, Mohan; Wang, Qiao; Gaseitsiwe, Simani; Moyo, Sikhulile; Kasvosve, Ishmael; Shin, Sanghyuk S.; Zetola, Nicola M.; Paganotti, Giacomo M.; Grover, Surbhi // International Journal of Cancer;Mar2020, Vol. 146 Issue 6, p1667 

    Cervical cancer remains a significant cause of morbidity and mortality in women worldwide and is the leading cause of cancer‐related death in Botswana. It is well established that women with HIV have a higher risk of persistent HPV infection leading to cervical cancer. We assessed HPV...

  • Monitoring the coverage and impact of human papillomavirus vaccine -- report of WHO meeting, November 2009.  // Weekly Epidemiological Record;6/18/2010, Vol. 85 Issue 25, p237 

    The article reports on the coverage and impact monitoring of the human pappilomavirus vaccine (HPV). It states that monitoring vaccine coverage of HPV is valuable in the evaluation of vaccine programs and vaccine impact. It also cites several possible biological resultants for the monitoring...

  • Human papillomavirus vaccination update: Nonavalent vaccine and the two-dose schedule. Brotherton, Julia M. L. // Australian Journal of General Practice;Jul2018, Vol. 47 Issue 7, p417 

    Background Australia has included quadrivalent human papillomavirus (HPV) vaccination in its national program since 2007. Significant declines have been observed in the incidence of HPV infection, genital warts and high-grade cervical lesions. In 2018, the program changed to a nonavalent HPV...

  • Quadrivalent Human Papillomavirus Vaccine. Barr, Eliav; Tamms, Gretchen // Clinical Infectious Diseases;9/1/2007, Vol. 45 Issue 5, p609 

    The lifetime risk of human papillomavirus (HPV) infection exceeds 50%. HPV infection causes >550,000 cases of cervical and anogenital cancer worldwide annually. Infection also causes precancerous lesions and genital warts. HPV types 16 and 18 cause ~70% of HPV-related cancers, and HPV types 6...

  • Quantifying the Decisional Satisfaction to Accept or Reject the Human Papillomavirus (HPV) Vaccine: A Preference for Cervical Cancer Prevention. Harper, Diane M.; Irons, Billy B.; Alexander, Natalie M.; Comes, Johanna C.; Smith, Melissa S.; Heutinck, Melinda A.; Handley, Sandra M.; Ahern, Debra A. // PLoS ONE;Feb2014, Vol. 9 Issue 2, p1 

    Objective: Only a portion of the US population is willing to consider HPV vaccination to date. The primary aim of this study is to determine the decisional satisfaction associated with HPV vaccination. Study Design: This is a prospective survey conducted at an urban college where women...

  • Community Involvement in Developing a Human Papillomavirus (HPV) Vaccine Brochure Made for Parents in Hawai'i. Dela Cruz, May Rose I.; Tsark, Jo Ann U.; Soon, Reni; Albright, Cheryl L.; Braun, Kathryn L. // Hawaii Journal of Medicine & Public Health;Jul2016, Vol. 75 Issue 7, p203 

    The article offers information on the importance of community involvement for the development of Human Papillomavirus (HPV) Vaccine. It states the impact of the vaccination for reduction of diseases such as cervical cancer, genital warts, and vulvar cancer. Also mentioned the role of physician...

  • Prevention of HPV-Related Cancers in Norway: Cost-Effectiveness of Expanding the HPV Vaccination Program to Include Pre-Adolescent Boys. Burger, Emily A.; Sy, Stephen; Nygård, Mari; Kristiansen, Ivar S.; Kim, Jane J. // PLoS ONE;Mar2014, Vol. 9 Issue 3, p1 

    Background: Increasingly, countries have introduced female vaccination against human papillomavirus (HPV), causally linked to several cancers and genital warts, but few have recommended vaccination of boys. Declining vaccine prices and strong evidence of vaccine impact on reducing HPV-related...

  • Estimating the number needed to vaccinate to prevent diseases and death related to human papillomavirus infection. Brisson, Marc; Van de Velde, Nicolas; De Wals, Philippe; Boily, Marie-Claude // CMAJ: Canadian Medical Association Journal;8/28/2007, Vol. 177 Issue 5, p464 

    Background: A vaccine against human papillomavirus (HPV) types 6, 11, 16 and 18 is now licensed for use in Canada and many other countries. We sought to estimate the number needed to vaccinate to prevent HPV-related diseases and death. Methods: A cohort model of the natural history of HPV...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics